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Human	 defensins	—	 small	 antimicrobial	 pep‑
tides	—	are	in	the	focus	of	numerous	researches	aimed	
on	evaluation	of	 their	structure,	biological	 functions	
and	patterns	of	expression	in vitro	and	in vivo in	normal	
state	and	upon	pathology	[1,	2].	Such	interest	to	these	
biomolecules	 is	due	to	recently	established	involve‑
ment	of	defensins	in	a	number	of	processes	important	
for	cell	behavior	—	proliferation,	differentiation,	growth	
and	death	[3–6].	On	multicellular	level,	these	antimi‑
crobials	are	taking	part	in	the	protection	of	host	from	
invading	pathogens,	functioning	of	immune	system,	
tissue	repair	and	tumorigenesis	[1,	2,	5,	7–13].
It	is	established	also	that	in	in vitro	models	produc‑
tion	of	defensin	and/or	exogenous	addition	of	defen‑
sins	to	the	cells	results	in	elevation	of	their	proliferation	
rate	[3,	4,	11].	At	the	same	time	the	mechanisms	me‑
diating	defensin‑dependent	cell	proliferation	remains	
poorly	 studied	yet	as	well	 as	potential	 intracellular	
targets	of	these	antimicrobials.
Up	to	date	the	data	on	involvement	of	defensins	in	
intracellular	signaling	are	scarce.	One	may	speculate	
that	unique	molecular	properties	of	defensins	 (am‑
phipatic	chain,	high	cationic	charge,	 low	molecular	
weight)	favor	their	interactions	with	subcellular	com‑
ponents,	plasma	membranes,	as	well	as	with	discrete	
membrane‑bound	and	cytoplasmic	proteins	—	com‑
ponents	of	 intracellular	 signaling	pathways.	 In	 few	
publications	the	role	of	defensins	in	activation	of	intra‑
cellular	signaling	cascades	in vitro	has	been	analyzed.	
It	has	been	reported	that	alpha‑defensin	may	interact	
with	LRP	receptor	expressed	in	smooth	muscle	cells	
(SMC),	undergo	internalization	and	specifically	inhibit	
protein	kinase	C	[14].	In	another	research	it	was	dem‑
onstrated	that	treatment	of	airway	SMC	with	HNP1–3	
leads	to	phosphorylation	of	extracellular	signal‑regu‑
lated	kinase	(ERK)	1/2	[15].	In	human	keratinocytes,	
hBD‑2,	‑3,	and	‑4‑dependent	secretion	of	IL‑18	was	
shown	 to	be	mediated	by	p38	and	ERK1/2	MAPK	
pathways	[16].	Human	cathelicidin	LL‑37	was	shown	to	
activate	MAPK/ERK	pathway	in	airway	epithelial	cells	
and	transactivate	EGFR	via	metalloproteinase‑medi‑
ated	cleavage	of	membrane‑anchored	EGFR‑ligands	
[17].	In	airway	epithelial	cells	treatment	with	HNP1–3	
caused	activation	of	 ERK1/2,	 and	 the	process	of	
HNP‑dependent	wound	repair	seems	to	be	dependent	
on	EGFR	activation	[9].
Our	previous	studies	have	shown	increase	of	cell	
proliferation	in vitro	upon	treatment	of	A431	cells	with	
exogenous	hBD‑2	 [4].	 The	present	 research	was	
aimed	on	identification	of	possible	molecular	targets	of	
hBD‑2	in	A431	cells	that	could	be	involved	in	mediation	
of	its	pro‑proliferative	action.
Materials and Methods
Cell cultures and cultivation. A431	(human	vulval	
epidermoid	carcinoma)	cells	were	received	from	the	
Institute	of	Molecular	Biology	of	Russian	Academy	of	
Sciences	(Moscow,	Russia).
A431	 cells	were	 cultivated	 in	 6–well	 plates	 in	
DMEM	culture	medium	supplemented	with	5%	FBS	
(Gibco	BRL,	UK)	 in	atmosphere	of	5%CO2	at	37	 °C	
until	cells	reached	70%	confluence;	then	the	medium	
was	replaced	with	DMEM	without	FBS	and	cultivation	
continued	for	24	h.	Then	the	cells	(5	х	105	cells	per	well)	
were	incubated	with	EGF	(10	ng/ml)	and/or	recombi‑
nant	hBD‑2	(1	µg/ml)	[18]	for	30	min,	12	h,	and	24	h	
for	kinase	assays,	RT‑PCR	analysis	of	expression	of	
p70S6K	on	mRNA	and	protein	levels,	respectively.
RT‑PCR‑analysis.	 For	detection	of	expression	
of	p70S6Kα	and	p70S6Kβ	semiquantative	RT‑PCR	
analysis	was	applied	as	described	 in	 [19].	The	next	
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primers	were	used:	direct	ones	—	5`‑ttggggcattta‑
catcaaaaggg	–	for	p70S6Kα	and	5`‑ggatcgccgccctt‑
taccgca	—	for	p70S6Kβ;	reverse	primer	5`‑cccag(a/g)	
aag(a/g)cctg(a/g)ttggcact	—	 for	 both	 genes.	
30	cycles	of	amplification	at	 regimen	 (94	°С	–	20	s,	
64	°С	—	30	s,	72	°С	—	45	s)	were	performed.	Expres‑
sion	of	glyceraldehyde‑3‑phosphate	dehydrogenase	
(G3PDH)	 (direct	primer	—	5′‑tgaaggtcggagtcaacg‑
gatttggt,	 reverse	primer	—	5′‑catgtgggccatgaggtc‑
caccac)	served	as	the	control	(25	cycles	at	the	regimen	
95	°С	—	20	s,	64	°С	—	30	s,	72	°С	—	45	s).	The	products	
of	RT‑PCR	were	routinely	analyzed	by	electrophoresis	
in	agarose	gel.
Western blot analysis, autophosphorylation of 
EGF‑receptor, kinase assays and cross‑linking 
technique.	Western‑blot	analysis	was	performed	by	
standard	procedure	with	the	use	of	the	next	antibod‑
ies:	MoAbs	against	full	size	molecule	of	p70S6Kα	[20],	
polyclonal	antibodies	against	C‑terminal	fragment	of	
p70S6Kβ	(Institute	of	Molecular	Biology	and	Genetics,	
NAS	of	Ukraine,	Kyiv,	Ukraine),	MoAbs	against	phos‑
phorylated	thyrosine	(PY20,	Santa	Cruz	Biotechnology	
INC,	USA),	MoAbs	against	EGFR	(Sigma,	USA),	phos‑
pho‑PDK1	mAbs	(Ser241),	phospho‑ERK1/2	(Thr202/
Tyr204),	phospho‑p38	MARK	(Thr180/Tyr182),	phos‑
pho‑MARK/JNK	(Thr183/Tyr185)	(CellSignaling	Tech,	
USA),	and	polyclonal	antibodies	against	ribosomal	S6	
protein	phosphorylated	at	 the	position	Ser235/236	
(CellSignaling	Tech,	USA).	The	data	of	Western‑blot	
analysis	were	analyzed	by	densitometry	using	Total‑
Lab	v1.10	programme	(the	results	were	recalculated	
by	loading	control	values).	Each	experiment	was	re‑
peated	in	triplicate.
Kinase	assay	was	performed	as	follow:	A431	cells	
were	cultivated	in	6–well	plates	(5	х	105	cells	per	well)	
for	24	h	in	DMEM	without	FBS;	then	cells	were	washed	
with	serum‑free	medium	and	incubated	in	HEPES‑PBS	
buffer	with	10	ng/ml	EGF	and/or	1	µg/ml	hBD‑2	for	
30	min.	Then	buffer	was	aspirated	and	the	cells	were	
immediately	 lysed	by	hot	 Laemmly	 sample	buffer.	
Then	 the	samples	were	subjected	 to	10	or	7–22%	
SDS‑PAGE	gradient	electrophoresis	and	Western‑blot	
analysis	was	carried	out	by	standard	schedule	using	
abovementioned	antibodies	and	developed	using	ECL	
kit	(Amersham,	UK).
For	 cross‑linking	 experiment	 for	 evaluation	 of	
formation	of	EGFR	dimers,	after	 incubation	of	cells	
with	hBD‑2	the	medium	was	removed	and	replaced	
with	BS3‑containing	buffer	 (Pierce,	USA)	 for	30	min	
at	37	°C	according	to	the	instructions	of	manufacturer.	
Then	100	ml	of	the	sample	buffer	were	added,	and	the	
proteins	were	analyzed	by	Western	blot	analysis.
results
influence hBD‑2 on activation of EGFR and 
down‑stream kinases. The	first	task	of	the	present	
research	was	to	analyze	possible	influence	of	hBD‑2	on	
activation	of	EGFR	receptor	in vitro.	For	that	purpose	
we	have	analyzed	the	autophosphorylation	level	of	EGF	
receptor	in	A431	cells	treated	with	recombinant	hBD‑2	
at	the	concentration	causing	maximal	increase	of	cell	
proliferation	in vitro	[4]	and	compared	the	content	of	
monomers	and	dimers	of	EGF	receptor	in	A431	cells	
upon	 influence	of	1	µg/ml	hBD‑2	and/or	10	ng/ml	
EGF	(used	as	positive	control).	Our	data	have	shown	
(Fig.	1)	that	30	min	treatment	of	A431	cells	with	hBD‑2	
did	not	influence	autophosphorylation	level	of	EGFR,	
but	decreased	the	level	of	formation	of	EGFR	dimers	
in	the	presence	of	EGF,	in	particular	if	15	min	pretreat‑
ment	with	hBD‑2	was	applied	prior	to	addition	of	EGF	
(Fig.	1,	line	5).
As	we	have	reported	earlier	[21],	the	treatment	of	
A431	cells	with	hBD‑2	does	not	cause	activation	of	
EGFR‑dependent	downstream	cascade,	 typical	 for	
classic	EGFR	ligand.	However,	in	A431	cells	incubated	
with	hBD‑2	for	30	min,	a	band	of	3–4	phosphorylated	
proteins	with	molecular	weights	of	40–60	kDa	appears,	
and	accumulation	of	these	products	lasts	till	24	h	of	
incubation.	Using	anti‑phospho‑ERK1/2,	 ‑MEK1/2,	
‑JNK1/2,	and	 ‑р38	mAbs,	we	have	estimated	 that	
incubation	of	A431	cells	with	hBD‑2	didn’t	influence	
phosphorylation	of	р38	and	JNK	kinases	 (data	not	
shown),	but	 resulted	 in	phosphorylation	of	MEK1/2	
and	ERK1/2	kinases	(Fig.	2).
influence hBD‑2 on activation of PDK1‑p70S6K 
pathway.	We	have	 find	out	 that	12	h	 incubation	of	
A431	cells	with	1	µg/ml	hBD‑2	resulted	in	a	marked	
fig. 1. Western	blot	analysis	of	autophosphorylation	of	EGF	
receptor	and	EGFR‑dimer	 formation	 in	A431	 incubated	with	
EGF	and/or	hBD‑2	 (A,	pY20	MoAbs).	Expression	of	EGFR	(B,	
anti‑EGFR‑MoAbs)	served	as	 loading	control. A431	cells	 (2	x	
105/well,	24‑well	plate)	were	cultured	24	h	without	FBS,	then	EGF	
(10	ng/ml)	and/or	hBD‑2	(1	µg/ml)	were	added	for	15–30	min.	In	
case	(a)	cells	were	treated	with	BS3	crosslinker.	Lines:	1	—	control	
cells;	2	— +	EGF,	30	min;	3	—	+	EGF	for	15	min,	then	+	hBD‑2	for	
15	min;	4	‑+	hBD‑2	for	30	min;	5	‑+	hBD‑2	for	15	min,	then	+	EGF	
for	15	min;	6	—	EGF	+	hBD‑2	simultaneously	for	30	min
fig 2. Western	blot	analysis	of	phosphorylation	of	MEK1/2	(a)	
and	ERK1/2	(b)	kinases	in	A431	cells	incubated	for	30	min	with	
1	µg/ml	hBD‑2	(line	2),	10	ng/ml	EGF	(line	3)	or	hBD2+EGF	(line	
4).	Line	1	—	control	A431	cells	without	inductors.	β‑actin	expres‑
sion	(anti‑β‑actin‑MoAbs	(Sigma,	USA)	(c)	served	as	control
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(nearly	2‑fold)	 increase	of	expression	of	mRNAs	for	
alpha‑	and	beta‑isoforms	of	p70S6	kinase	 that	was	
close	 to	 that	upon	 treatment	of	cells	with	10	ng/ml	
EGF	(Fig.	3).	Western	blot	analysis	of	expression	of	
p70S6K	isoforms	in	A431	cells	after	24	h	incubation	
of	 the	cells	with	1	µg/ml	hBD‑2	has	demonstrated	
the	 similar	pattern	—	defensin	 strongly	 influenced	
production	of	alpha‑	and	beta‑isoforms	of	p70S6	in	
A431	cells	 (by	3‑fold	and	2‑fold,	 respectively)	and	
elevation	of	 the	activity	of	 the	p70S6	kinase	(Fig.	4,	
Fig.	5,	a).	Moreover,	PDK1	—	the	up‑stream	kinase	
phosphorylating	p70S6K	–	is	also	found	to	be	nearly	
2‑fold	higher	phosphorylated	in	A431	cells	incubated	
with	1	µg/ml	hBD‑2	 for	30	min	compared	 to	 that	 in	
control	cells	(Fig.	5).
discussion
In	the	present	research	we	aimed	to	evaluate	pos‑
sible	involvement	of	EGFR	in	hBD‑2	dependent	cell	sig‑
naling.	Our	previous	data	[4]	have	demonstrated	that	
in	micromolar	concentration	range	exogenous	hBD‑2	
promotes	proliferation	of	cultured	cells	 in vitro	 and	
the	rate	of	hBD‑2–dependent	proliferation	correlates	
with	the	content	of	EGFR	in	given	cells.	Moreover,	we	
have	observed	that	simultaneous	stimulation	of	A431	
cells	with	EGF	and	hBD‑2	resulted	in	the	decrease	of	
incorporation	of	 [3H]‑thymidine	compared	with	 that	
for	cells	 treated	separately	with	hBD‑2	or	EGF	 (un‑
published	data).	That’s	why	we	 tried	 to	analyze	 the	
autophosphorylation	level	of	EGF	receptor	in	A431	cells	
treated	with	micromolar	concentration	of	hBD‑2	and	to	
evaluate	the	content	of	monomers	and	dimers	of	EGF	
receptor	in	A431	cells	upon	influence	of	hBD‑2	and/or	
EGF.	Our	data	have	shown	that	short‑term	treatment	
of	A431	cells	with	hBD‑2	did	not	influence	the	level	of	
autophosphorylation	of	EGFR,	but	seems	too	decrease	
the	level	of	formation	of	EGFR	dimers	in	the	presence	
of	EGF.	We	hypothesize	that	there	could	be	at	least	two	
possible	explanations	of	such	phenomenon:	1)	hBD‑2	
may	penetrate/intercalate	cell	membrane	due	to	well‑
fig. 3. RT‑PCR	analysis	of	expression	of	mRNA	for	p70S6	kinase,	isoform	alpha	(a)	and	p70S6	kinase,	isoform	beta	(b)	in	A431	
cells.	G3PDH	expression	(c)	served	as	control.	А431	cells	were	grown	in	6‑well	plates	(5	x	105	cells	per	well)	till	70%	monolayer,	
than	the	medium	was	replaced	by	serum‑free	one	for	24	h.	Then	cells	were	treated	with	10	ng/ml)	EGF	and/or	1	µg/ml	hBD‑2	for	
12	h.	Lanes:	1	—	control;	2	—	+	EGF;	3	‑+	FBS;	4	—	EGF	+	hBD‑2;	5	—	hBD‑2;	M	—	DNA	1	kb	ladder
fig. 4. Western	blot	analysis	of	expression	of	p70S6	kinase,	isoform	alpha	(a),	p70S6	kinase,	isoform	beta	(b).	β‑actin	expres‑
sion	(anti‑β‑actin‑MoAbs	(Sigma,	USA)	(c)	served	as	control.	А431	cells	were	grown	in	6‑well	plates	(5	x	105	cells	per	well)	till	70%	
monolayer,	than	the	medium	was	replaced	by	serum‑free	one	for	24	h.	Then	the	cells	were	treated	with	10	ng/ml	EGF	and/or	1	µg/ml	
hBD‑2	for	24	h.	Lanes:	1	—	control;	2	—	+	EGF;	3	‑+	FBS;	4	—	EGF	+	hBD‑2;	5	—	hBD‑2
fig. 5. Western	blot	analysis	of	phosphorylation	level	of	ribosomal	S6	protein	(Ser235/236)	(a)	and	PDK1	(Ser241)	(b)	in	A431	cells.	
β‑actin	expression	(anti‑β‑actin‑MoAbs	(Sigma,	USA))	(c)	served	as	control.	А431	cells	were	grown	in	6‑well	plates	(5	x	105	cells	per	
well)	till	70%	monolayer,	than	the	medium	was	replaced	by	serum‑free	one	for	24	h.	Then	the	cells	were	treated	with	10	ng/ml	EGF	
and/or	1	µg/ml	hBD‑2	for	30	min.	Lanes	(a	and	c):	1	—	control;	2	—	+	EGF;	3	‑+	FBS;	4	—	EGF	+	hBD‑2;	5	—	hBD‑2;	b:	1	—	control;	
2	—	+	EGF;	3	—	hBD‑2	(15	min)	+	EGF	for	15	min;	4	—	EGF	(15	min)	+	hBD‑2	for	15	min;	5	—	hBD‑2
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known	membrane‑permebealizing	properties	of	anti‑
microbial	pepties	thus	preventing	dimer’s	formation;	
2)	hBD‑2	may	non‑specifically	bind	 to	EGF‑binding	
site	of	EGF	receptor	due	to	 its	steric	homology	with	
EGF	molecule	[22],	however,	without	further	dimer‑
ization/activation	of	 receptor.	Our	data	have	shown	
that	action	of	hBD‑2	 in vitro	 is	different	 from	that	of	
HNP‑1	on	airway	epithelial	cells	[17],	where	transient	
activation	of	EGFR	realized	via	activation	of	metallopro‑
teinase‑mediated	cleavage	of	membrane‑anchored	
EGFR‑ligands	has	been	observed.
Taking	 into	account	 the	data	of	other	authors	[15,	
16]	on	possible	 involvement	of	MAP‑kinase	pathway,	
in	particular	ERK1/2	kinase,	 in	mediation	of	action	of	
defensins	 in vitro,	we	carried	out	 the	research	of	 the	
phosphorylation	state	of	some	kinases	of	MAP‑kinase	
pathway	in	A431	cells	treated	with	hBD‑2	and	have	shown	
hBD‑2‑dependent	activation	of	MEK1/2	and	ERK1/2	ki‑
nases.	Mentioned	kinases	are	evolutionary	conservative	
proteins	that	link	surface	cell	receptors	with	key	regula‑
tory	molecules	and	control	cell	survival	and	adaptation.	
It	is	known	that	phosphorylation	of	MEK1/2	and	ERK1/2	
leads	to	activation	of	different	transcriptional	factors	(in	
particular	АР‑1	and	NF‑kB),	and	initiation	of	prolifera‑
tion,	growth	and	differentiation	of	cells	[23,	24].	Our	data	
points	on	involvement	of	MEK1/2	and	ERK1/2	in	media‑
tion	of	action	of	hBD‑2	in	A431	cells.	Unfortunately,	we	
are	unable	yet	to	determine	up‑stream	kinases	mediating	
hBD‑2‑dependent	phosphorylation	of	ERK	1/2.
Mitogenic	properties	of	hBD‑2	make	it	reasonable	
to	research	its	influence	on	expression	patterns	and	
activity	of	p70S6	kinase	—	key	enzyme	of	the	system	
of	protein	biosynthesis,	 that	 is	hyperactivated	upon	
mitogenic	influence	of	growth	factors	in vitro.	We	have	
find	out	that	incubation	of	A431	cells	with	micromolar	
concentrations	of	hBD‑2	resulted	in	a	marked	increase	
of	expression	of	mRNAs	and	respective	protein	prod‑
ucts	of	alpha‑	and	beta‑isoforms	of	p70S6	kinase	as	
well	as	activity	of	 the	kinase.	Such	up‑regulation	of	
p70S6	kinase	expression	and	activity	may	be	in	part	
explained	by	 the	detected	defensin‑dependent	el‑
evation	of	phosphorylation	of	PDK1	—	the	up‑stream	
kinase	that	phosphorylates	p70S6K	[25].
As	 far	as	we	know	 it	 is	a	 first	 report	on	 involve‑
ment	of	defensins	in	regulation	of	enzymes	control‑
ling	protein	biosynthesis.	PDK1	 is	playing	a	central	
role	as	activator	of	multiple	signaling	pathways,	that	
may	be	affected	upon	carcinogenesis,	 in	particular	
protein	synthesis.	The	obtained	data	do	not	allow	us	
yet	 to	propose	 the	exact	mechanism	of	 interaction	
between	hBD‑2	and	PDK1‑signaling	cascade.	How‑
ever,	one	may	speculate	that	such	effect	possibly	may	
relay	in	direct	interaction	between	plasma‑membrane	
bound	PDK1	and	defensin	—	according	to	data‑base	
(www.scansite.mit.edu)	there	is	extremely	high	affinity	
between	hBD‑2	and	PDK1	molecules.	Our	preliminary	
data	based	on	pull‑down	technique	for	PDK‑1‑hBD‑2	
(data	not	shown)	also	point	on	the	possibility	of	such	
interactions.	We	hope	that	new	studies	with	the	use	
of	recombinant	defensins	will	put	new	insight	on	the	
role	of	these	multifunctional	antibiotics	in	cell	signal‑
ing	and	behavior.
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участие бета-дефенсина-2 человека в передаче 
внутриклеточных сигналов in viTRo
Цель: проанализировать участие бета-дефенсина-2 человека (hBD-2) в механизмах передачи внутриклеточных сигналов 
в модели in vitro. Материалы и методы: клетки линии A431 культивировали в присутствии 1 µг/мл рекомбинантного hBD-2 
и/или 10 нг/мл ЭФР. Экспрессию мРНК альфа- и бета-изоформ p70S6 киназы оценивали методом полуколичественного 
ОТ-ПЦР анализа. Экспрессию и активность p70S6K, фосфорилирование PDK1, ERK, JNK, p38 киназ и рецептора 
ЭФР (ЭФРР) исследовали методом Вестерн-блот анализа. Результаты: 30 мин инкубация клеток A431 с 1 µг/мл hBD-2 
не оказывала влияния на уровень аутофосфорилирования ЭФРР, но препятствовала образованию димеров рецептора 
в присутствии ЭФР. В то же время 30 мин обработка клеток hBD-2 приводила к активации p70S6K, 12 ч — к значительному 
повышению уровня мРНК альфа- и бета-изоформ p70S6 киназы, а 24 ч — к повышению синтеза p70S6K на уровне белка. 
PDK1-киназа, фосфорилирующая p70S6K, также подвергалась фосфорилированию в присутствии экзогенного hBD-2 in vitro. 
Выводы: данные свидетельствуют об участии каскада PDK1-p70S6K в опосредовании действия hBD-2 в клетках A431.
Ключевые слова: бета-дефенсин-2 человека, ЭФР, рецептор ЭФР, p70S6 киназа, PDK1.
